OR7E24

Across TCGA pan-cancer cohorts, OR7E24 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OR7E24 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher OR7E24 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR7E24 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC, LUAD, and UCEC are the cancer types where OR7E24 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.098	0.777	<.001	12	view →
LUAD	OS	Median	III,IV	0.004	0.665	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	II,III,IV	0.987	0.830	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

OR7E24–LIHC (OS)

Open the LIHC breakdown →